IMMUNOR AS
home - Immunor AS
Immunor AS is a Norwegian-based vaccine developer unlike any other. Building on comprehensively patented IP of unique elegance and power, Immunor AS is in
Keywords
researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors
Links
Organization
- CEO
- AS
- Chairman of the board
- BS
Birger Sørensen1955
- Years since formation
- 11 years
- since Nov 13, 2014
- Type
- Limited company
- VAT registered
- No
- Number of employees
- 0
Ownership
- Number of shares and share classes
- 553,705,360
- 1 share class
- Total number of shareholders
- 35
- 24 companies, 11 persons
Financials
- Annual total result 2023
- -417,741
- NOK
- Total equity 2023
- -3,127,376
- NOK
Last update: Aug 29, 2024
Management
Management / administration
| Name | Role | Shares |
|---|---|---|
AS | Managing Director/CEO | 22.03 % indirectly |
Board
| Name | Role | Shares |
|---|---|---|
BS 1955 | Chairman | 30.81 % indirectly |
AA 1959 | Board Member | 2.97 % indirectly |
DA | Board Member | 3.29 % indirectly |
Others
| Name | Role | Shares |
|---|---|---|
| Auditor | - | |
| Accountant | - |
Top 10 individual shareholders
| Name | Role | Shares |
|---|---|---|
BS 1955 | Chairman | 30.81 % indirectly |
AS | Managing Director/CEO | 22.03 % indirectly |
HS | - | 11.02 % indirectly |
DA | Board Member | 3.29 % indirectly |
AA 1959 | Board Member | 2.97 % indirectly |
JM | - | 1.35 % indirectly |
RS | - | 1.35 % indirectly |
Last update: May 13, 2024
Ownership
Company shareholders
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| Ordinary shares | 183,009,643 | 33.05 % | |
| Ordinary shares | 170,575,483 | 30.81 % | |
| Ordinary shares | 72,707,891 | 13.13 % | |
| Ordinary shares | 18,227,631 | 3.29 % | |
| Ordinary shares | 16,427,629 | 2.97 % | |
| Ordinary shares | 11,562,113 | 2.09 % | |
| Ordinary shares | 10,500,000 | 1.9 % | |
| Ordinary shares | 7,462,687 | 1.35 % | |
| Ordinary shares | 7,462,687 | 1.35 % | |
| Ordinary shares | 6,818,028 | 1.23 % | |
| Ordinary shares | 6,043,310 | 1.09 % | |
| Ordinary shares | 5,000,000 | 0.9 % | |
KS 1978 | Ordinary shares | 5,000,000 | 0.9 % |
| Ordinary shares | 4,524,524 | 0.82 % | |
| Ordinary shares | 4,000,000 | 0.72 % | |
| Ordinary shares | 3,136,360 | 0.57 % | |
| Ordinary shares | 2,551,520 | 0.46 % | |
| Ordinary shares | 2,523,303 | 0.46 % | |
| Ordinary shares | 2,045,410 | 0.37 % | |
GU 1963 | Ordinary shares | 1,841,791 | 0.33 % |
| Ordinary shares | 1,729,316 | 0.31 % | |
| Ordinary shares | 1,551,804 | 0.28 % | |
| Ordinary shares | 1,551,804 | 0.28 % | |
| Ordinary shares | 1,503,134 | 0.27 % | |
| Ordinary shares | 1,200,000 | 0.22 % | |
DA | Ordinary shares | 1,052,936 | 0.19 % |
| Ordinary shares | 853,561 | 0.15 % | |
| Ordinary shares | 805,687 | 0.15 % | |
CB | Ordinary shares | 608,776 | 0.11 % |
OL 1963 | Ordinary shares | 340,900 | 0.06 % |
TI | Ordinary shares | 340,138 | 0.06 % |
ØM | Ordinary shares | 204,540 | 0.04 % |
PS 1952 | Ordinary shares | 200,000 | 0.04 % |
| Ordinary shares | 200,000 | 0.04 % | |
| Ordinary shares | 142,754 | 0.03 % |
Shares owned by the IMMUNOR AS
| Name | Share class | Total number of shares | Share |
|---|---|---|---|
| NO0010813736 | 16,350,000 | 35.87 % |
Last update: Jun 2, 2025
Financials
in NOK
Summary
| Year | 2023 | 2021 |
|---|---|---|
Total operating income | 0 | 305,043 |
Annual Total Result | -417,741 | -223,336 |
Total assets | 53,205 | 176,599 |
Total liabilities | 3,180,581 | 2,000,772 |
Total equity | -3,127,376 | -1,824,173 |
P&L
| Year | 2023 | 2021 |
|---|---|---|
Total operating income | 0 | 305,043 |
Total operating costs | 172,295 | 567,114 |
Operating result | -172,295 | -262,071 |
Financial income/costs | -245,446 | 38,735 |
Profit before tax | -417,741 | -223,336 |
Total tax & extraordinary income/cost | 0 | 0 |
Annual Total Result | -417,741 | -223,336 |
Balance overview
| Year | 2023 | 2021 |
|---|---|---|
Total fixed assets | 36,216 | 126,600 |
Total current assets | 16,989 | 49,999 |
Total assets | 53,205 | 176,599 |
Short term debt | 710,586 | 248,872 |
Long term debt | 2,469,995 | 1,751,900 |
Total liabilities | 3,180,581 | 2,000,772 |
Contributed capital | 50,550 | 24,334 |
Retained earnings | -3,177,927 | -1,848,507 |
Total equity | -3,127,376 | -1,824,173 |
Total equity and liabilities | 53,205 | 176,599 |
Classification
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology